Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

January is often a time for setting health goals, with weight loss topping many New Year’s resolutions. As people explore the best path forward, they may encounter a variety of ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.